resistanceBio
Private Company
Harnessing evolution to overcome treatment-resistant cancer.
Pharmaceutical Manufacturing
San Carlos, California
11-50 employees
Founded 2019
About resistanceBio
Resistance Bio is a biotechnology company dedicated to overcoming cancer treatment resistance through its proprietary platforms and therapeutics. It offers the ResCu Platform to predict cancer therapy responses and ENCER models to identify resistance mechanisms, primarily for pharmaceutical and biotech partners. The company also develops its own multitargeted therapeutics designed to proactively address tumor evolution and drug resistance.
Company Classification
Customer Types
B2B
Business Models
ProductsServicesLicensing
Product & Service Types
Cancer resistance prediction platformMultitargeted cancer therapeuticsDrug development cancer models
Funding
Total Funding
$24.78M
No. of Funding Rounds
5
Customers
| Customer | Success Story | Source |
|---|---|---|
| Utilized the platform to tackle rapidly mutating pathogens by targeting conserved weak points in viruses. Developed broadly neutralizing antibodies. Manipulated IP for bioengineering and manufacturing. Centivax is using a platform approach to tackle quickly-mutating pathogens by focusing on conserved weak points in viruses. Their core IP is a solution to trigger the body's defenses towards these conserved sites. | ||
| Utilized the platform to tackle rapidly mutating pathogens by targeting conserved weak points in viruses. Developed broadly neutralizing antibodies. Manipulated IP for bioengineering and manufacturing. Centivax is using a platform approach to tackle quickly-mutating pathogens by focusing on conserved weak points in viruses. Their core IP is a solution to trigger the body's defenses towards these conserved sites. |
Sign up to Ethos to access the full customer list, plus detailed competitor and product analysis.
Sign up to Ethos